These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 19719728)

  • 1. FTY720 and everolimus in de novo renal transplant patients at risk for delayed graft function: results of an exploratory one-yr multicenter study.
    Tedesco-Silva H; Lorber MI; Foster CE; Sollinger HW; Mendez R; Carvalho DB; Shapiro R; Rajagopalan PR; Mayer H; Slade J; Kahan BD;
    Clin Transplant; 2009; 23(5):589-99. PubMed ID: 19719728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence of delayed graft function and wound healing complications after deceased-donor kidney transplantation is not affected by de novo everolimus.
    Albano L; Berthoux F; Moal MC; Rostaing L; Legendre C; Genin R; Toupance O; Moulin B; Merville P; Rerolle JP; Bayle F; Westeel PF; Glotz D; Kossari N; Lefrançois N; Charpentier B; Blanc AS; Di Giambattista F; Dantal J;
    Transplantation; 2009 Jul; 88(1):69-76. PubMed ID: 19584683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exposure-efficacy relationships of a fingolimod-everolimus regimen in kidney transplant patients at risk for delayed graft function.
    Kovarik JM; Tedesco-Silva H; Lorber MI; Foster C
    Transplant Proc; 2006 Dec; 38(10):3479-82. PubMed ID: 17175310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of de novo or early everolimus with low cyclosporine in deceased-donor kidney transplant recipients at specified risk of delayed graft function: 12-month results of a randomized, multicenter trial.
    Dantal J; Berthoux F; Moal MC; Rostaing L; Legendre C; Genin R; Toupance O; Moulin B; Merville P; Rerolle JP; Bayle F; Westeel PF; Glotz D; Kossari N; Lefrançois N; Charpentier B; Quéré S; Di Giambattista F; Cassuto E;
    Transpl Int; 2010 Nov; 23(11):1084-93. PubMed ID: 20500493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimal everolimus concentration is associated with risk reduction for acute rejection in de novo renal transplant recipients.
    Chan L; Hartmann E; Cibrik D; Cooper M; Shaw LM
    Transplantation; 2010 Jul; 90(1):31-7. PubMed ID: 20517177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FTY720, a novel immunomodulator: efficacy and safety results from the first phase 2A study in de novo renal transplantation.
    Tedesco-Silva H; Mourad G; Kahan BD; Boira JG; Weimar W; Mulgaonkar S; Nashan B; Madsen S; Charpentier B; Pellet P; Vanrenterghem Y
    Transplantation; 2004 Jun; 77(12):1826-33. PubMed ID: 15223899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of chronic allograft nephropathy at late stages using everolimus or FTY720 in combination with cyclosporine.
    Roos M; Liu S; Strobl M; Schmaderer C; Baumann M; Heemann U; Lutz J
    Transplant Proc; 2008 Dec; 40(10):3731-6. PubMed ID: 19100477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multicenter trial of everolimus in pediatric renal transplant recipients: results at three year.
    Ettenger R; Hoyer PF; Grimm P; Webb N; Loirat C; Mahan JD; Mentser M; Niaudet P; Offner G; Vandamme-Lombaerts R; Hexham JM;
    Pediatr Transplant; 2008 Jun; 12(4):456-63. PubMed ID: 18466433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multicenter, randomized study of the use of everolimus with tacrolimus after renal transplantation demonstrates its effectiveness.
    Chan L; Greenstein S; Hardy MA; Hartmann E; Bunnapradist S; Cibrik D; Shaw LM; Munir L; Ulbricht B; Cooper M;
    Transplantation; 2008 Mar; 85(6):821-6. PubMed ID: 18360262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
    Bumbea V; Kamar N; Ribes D; Esposito L; Modesto A; Guitard J; Nasou G; Durand D; Rostaing L
    Nephrol Dial Transplant; 2005 Nov; 20(11):2517-23. PubMed ID: 15985508
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term results of kidney transplantation with cyclosporine- and everolimus-based immunosuppression.
    Iaria G; Pisani F; Iorio B; Lucchesi C; De Luca L; Ielpo B; D'Andria D; Tariciotti L; Tisone G
    Transplant Proc; 2006 May; 38(4):1018-9. PubMed ID: 16757249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial.
    De Simone P; Metselaar HJ; Fischer L; Dumortier J; Boudjema K; Hardwigsen J; Rostaing L; De Carlis L; Saliba F; Nevens F
    Liver Transpl; 2009 Oct; 15(10):1262-9. PubMed ID: 19790150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors and consequences of delayed graft function in deceased donor renal transplant patients receiving antithymocyte globulin induction.
    Patel SJ; Duhart BT; Krauss AG; Moore LW; Egidi MF; Amiri HS; Gaber LW; Gaber AO
    Transplantation; 2008 Jul; 86(2):313-20. PubMed ID: 18645496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Everolimus with very low-exposure cyclosporine a in de novo kidney transplantation: a multicenter, randomized, controlled trial.
    Salvadori M; Scolari MP; Bertoni E; Citterio F; Rigotti P; Cossu M; Dal Canton A; Tisone G; Albertazzi A; Pisani F; Gubbiotti G; Piredda G; Busnach G; Sparacino V; Goepel V; Messa P; Berloco P; Montanaro D; Veroux P; Federico S; Bartezaghi M; Corbetta G; Ponticelli C
    Transplantation; 2009 Nov; 88(10):1194-202. PubMed ID: 19935373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
    Gaber AO; Kahan BD; Van Buren C; Schulman SL; Scarola J; Neylan JF;
    Transplantation; 2008 Nov; 86(9):1187-95. PubMed ID: 19005398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of FTY720 (fingolimod) on vasodilatory function and arterial elasticity in renal transplant patients.
    Westhoff TH; Schmidt S; Glander P; Liefeld L; Martini S; Offermann G; Neumayer HH; Zidek W; van der Giet M; Budde K
    Nephrol Dial Transplant; 2007 Aug; 22(8):2354-8. PubMed ID: 17526535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FTY720 immunomodulation: optimism for improved transplant regimens.
    Ferguson R
    Transplant Proc; 2004 Mar; 36(2 Suppl):549S-553S. PubMed ID: 15041404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclosporine reduction in the presence of everolimus: 3-month data from a Canadian pilot study of maintenance cardiac allograft recipients.
    Ross H; Pflugfelder P; Haddad H; Cantarovich M; White M; Ignaszewski A; Howlett J; Vaillancourt M; Dorent R; Burton JR;
    J Heart Lung Transplant; 2008 Feb; 27(2):197-202. PubMed ID: 18267227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Everolimus in clinical practice--renal transplantation.
    Pascual J
    Nephrol Dial Transplant; 2006 Jul; 21 Suppl 3():iii18-23. PubMed ID: 16815852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
    Schena FP; Pascoe MD; Alberu J; del Carmen Rial M; Oberbauer R; Brennan DC; Campistol JM; Racusen L; Polinsky MS; Goldberg-Alberts R; Li H; Scarola J; Neylan JF;
    Transplantation; 2009 Jan; 87(2):233-42. PubMed ID: 19155978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.